News | February 12, 2009

Medipattern Launches B-CAD-FOR-LIFE

February 12, 2009 - The Medipattern Corp. said its new sales model for accessing the benefits of B-CAD offers all of the separate components that are required to install, train, use and maintain B-CAD as one package under one monthly service fee.

Medipattern is aiming to effectively manage the service of providing computer-aided detection (CAD) for breast ultrasound imaging for its customers with the B-CAD-FOR-LIFE plan.

"We first spotted B-CAD for the benefits that it could offer our practice early last year, but we are a small business on a tight budget," said Olga Tsireshkin, M.D., founder of XXI Century Radiology and Imaging, P. C. located in Brooklyn, NY. "With B-CAD-FOR-LIFE, Medipattern still owns its asset, B-CAD; installs it, trains our staff in how to use it and maintains it for a monthly fee. This can give XXI Century immediate access to all of the benefits of B-CAD: saving time in documenting each case, improving communication of detailed information, that CAD second opinion, and reimbursement for the procedure in an affordable package. Another important benefit we gain is reporting, before B-CAD we paid a transcription fee for every line on every report, with B-CAD the information is communicated in a concise report - as an automatic part of the procedure. This eliminates transcription fees, reduces human errors, and saves our radiologists the time that they had spent double checking their reports. Our sonographers can make detailed notes electronically now and our radiologists review the Sonographer worksheet plus the CAD information. B-CAD is much more efficient."

For more information:

Related Content

Artificial Intelligence Performs As Well As Experienced Radiologists in Detecting Prostate Cancer
News | Artificial Intelligence | April 18, 2019
University of California Los Angeles (UCLA) researchers have developed a new artificial intelligence (AI) system to...
Oxipit Introduces Multilingual Support for ChestEye AI Imaging Suite
News | Artificial Intelligence | April 16, 2019
The CE-certified ChestEye artificial intelligence (AI) imaging suite by Oxipit is now available in seven European...
iCAD Appoints Stacey Stevens as President
News | Radiology Business | April 16, 2019
iCAD Inc. recently announced that Stacey Stevens has been named president. As president, Stevens will have expanded...
Enlitic Closes Series B Funding for Artificial Intelligence Solutions for Radiologists
News | Artificial Intelligence | April 08, 2019
Radiology artificial intelligence (AI) company Enlitic announced the close of its $15 million Series B financing round...
iCAD Highlighting ProFound AI for Tomosynthesis at 2019 SBI Annual Symposium
News | Computer-Aided Detection Software | April 04, 2019
iCAD announced it will present its latest artificial intelligence (AI) software solution for digital breast...
A smart algorithm developed by iCAD

A smart algorithm developed by iCAD outlines and scores a suspicious lesion seen in an image created using digital breast tomography. Displayed is the probability calculated by the algorithm that the outlined area includes a cancerous lesion. Image courtesy of Emily Conant, M.D.

Feature | Artificial Intelligence | April 03, 2019 | Greg Freiherr
  Editor's Note: This article was updated following the SBI symposium.  
Siemens Healthineers Debuts AI-Rad Companion Chest CT
News | Artificial Intelligence | January 25, 2019
Siemens Healthineers presented its first intelligent software assistant for radiology, the AI-Rad Companion Chest CT,...
Telerad Tech Launches MammoAssist AI Software
Technology | Computer-Aided Detection Software | January 25, 2019
Telerad Tech recently announced the launch of MammoAssist, a new artificial intelligence (AI) product to analyze and...
Videos | Artificial Intelligence | December 13, 2018
ITN Editor Dave Fornell and ITN Contributing Editor Greg Freiherr share their insights on the vendors showing...
FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...